10% Owner ADAR1 Capital Management Pours $1.6M into NextCure at $4.80–$5.00
NXTC has more than doubled off its 52-week low of $1.55 on light trading volume (0.2× avg).
Summary
10% owner ADAR1 Capital Management bought $1.6M of NextCure stock at $4.80–$5.00, increasing its stake to 722,419 shares. The purchase comes amid a pending merger that will heavily dilute existing holders.
Key Events · Ownership and Investor Activity · NXTC
-
$1.6M Purchase by 10% Owner
ADAR1 Capital Management and Daniel Schneeberger acquired 329,153 shares for $1,624,120.50 at prices ranging from $4.80 to $5.00 on July 30–31, 2026.
-
Stake Increased to 722,419 Shares
Post-transaction holdings total 722,419 shares, representing a significant increase from the prior 393,266 shares reported on July 29.
-
Merger Context
The purchase follows the July 14 announcement of a merger with Avere Therapeutics that will leave legacy NextCure stockholders with only ~1.89% of the combined company.
-
Financial Investor Signal
As a 10% owner, ADAR1's purchase reflects portfolio conviction rather than operational insider knowledge, but the size and timing near the merger vote suggest a bet on value realization.
Analysis · NXTC · Life Sciences
A $1.6 million purchase of NextCure stock by 10% owner ADAR1 Capital Management over two days, at prices near the current $4.17 level, signals a significant commitment from a large institutional holder. The move comes just weeks after the company announced a merger that would leave legacy shareholders with only ~1.89% of the combined entity, suggesting the fund sees value in the current price—potentially as a bet on the merger closing or on the underlying pipeline. Because the buyer is a 10% owner rather than a company executive, the signal is financial rather than operational: it reflects portfolio conviction, not insider knowledge of business developments.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 35.4% of the 1170 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NXTC was trading at $4.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.9M. The 52-week trading range was $1.55 to $15.74. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.